[CAS NO. 1628502-91-9] MW-150

Name: MW-150
Brand: Arctom Scientific
SKU: AS940605

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [1628502-91-9]

Distributor

Catalog

AS940605

Brand

Arctom Scientific

CAS

1628502-91-9

DESCRIPTION [1628502-91-9]

Overview

MDL	-
Molecular Weight	381.47
Molecular Formula	C24H23N5
SMILES	CN1CCN(C2=NN=C(C3=CC=C4C=CC=CC4=C3)C(C5=CC=NC=C5)=C2)CC1

For research use only. We do not sell to patients.

Summary

MW150 (MW01-18-150SRM) is a selective, CNS penetrant, and orally active inhibitor of p38α MAPK with a K _i of 101 nM. MW-150 inhibits the ability of the endogenous p38α MAPK to phosphorylate an endogenous substrate MK2 in activated glia ^[1] .

IC50 & Target

p38α

101 nM (Ki)

In Vitro

MW-150 inhibits in a concentration-dependent manner the ability of the endogenous p38α MAPK to phosphorylate an endogenous substrate MK2 in activated glia ^[1] .
MW-150 blocks in a concentration-dependent manner the increased IL-1β production by activated glia. The IC ₅₀ values are 332 nM and 936 nM for MK2 and IL-1β, respectively ^[1] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

MW-150 (2.5 mg/kg; oral daily for 3-4 months) improves the APP/PS1 transgenic (Tg) mice performance in radial arm water maze (RAWM) and contextual fear conditioning tests ^[1] .
MW-150 (2.5 mg/kg; given i.p.; daily for 14 days) treatment in APP ^NLh/NLh × PS ^P264L/P264L knock-in mouse (with no overexpression of the amyloid precursor protein) exhibits RAWM behavior indistinguishable from WT mice ^[1] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	APP/PS1 transgenic (Tg) mouse (overexpresses amyloid-beta) ^[1]
Dosage:	2.5 mg/kg
Administration:	Oral daily; 3-4 months (until cognitive impairment is present)
Result:	Improved the Tg mice performance in radial arm water maze (RAWM) and contextual fear conditioning tests.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase
NCT05194163	Neurokine Therapeutics\|Columbia University\|National Institute on Aging (NIA)	Alzheimer Disease	May 1, 2022	Phase 2

Appearance

Solid

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMSO : 40 mg/mL ( 104.86 mM ; Need ultrasonic)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.6214 mL	13.1072 mL	26.2144 mL
5 mM	0.5243 mL	2.6214 mL	5.2429 mL
10 mM	0.2621 mL	1.3107 mL	2.6214 mL

* Please refer to the solubility information to select the appropriate solvent.

In Vivo:

1.

Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline

Solubility: ≥ 3 mg/mL (7.86 mM); Clear solution
2.

Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)

Solubility: ≥ 3 mg/mL (7.86 mM); Clear solution
3.

Add each solvent one by one: 10% DMSO >> 90% corn oil

Solubility: ≥ 3 mg/mL (7.86 mM); Clear solution

* All of the co-solvents are available by MCE.

References

[1] Roy SM, et al. Targeting human central nervous system protein kinases: An isoform selective p38αMAPK inhibitor that attenuates disease progression in Alzheimer's disease mouse models. ACS Chem Neurosci. 2015 Apr 15;6(4):666-80.